Abstract:Circulation, Volume 146, Issue Suppl_1, Page A9318-A9318, November 8, 2022. Introduction:Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have demonstrated to be effective therapeutic agents for lowing low-density lipoprotein cholesterol (LDL-C). Ebronucimab (AK102) is a novel fully human immunoglobulin G1 (IgG1) monoclonal antibody against PCSK9. The objective of this study is to investigate the safety and tolerability of ebronucimab in healthy subjects.Methods:A total of 32 healthy adult subjects were planned to be enrolled and treated in a dose escalation manner. In each cohort, 8 subjects were randomized in a 3:1 ratio to receive a single dose of ebronucimab (75, 150, 300 or 500 mg) or matching placebo via subcutaneous injection (Figure 1). Blood was drawn at pre-selected timepoints to evaluate the pharmacokinetic parameters, free PCSK9 concentration and anti-drug antibody (ADA). Safety assessment was carried out up to day 85 ± 3 or early termination visit.Results:Safety Among the 32 subjects recruited, 87.5% (21/24) subjects administrated ebronucimab and 75% (6/8) subjects treated with placebo reported treatment emergent adverse events (TEAEs). The majority of adverse events were mild and moderate in severity. No relationship was identified between the dose of ebronucimab and the incidence of TEAEs. No TEAEs leading to study discontinuation and death were reported.Pharmacokinetics (PK)/Pharmacodynamics (PD)Following a single subcutaneous injection of 75 mg to 500 mg ebronucimab in healthy subjects, the median of Tmaxranged from 2.0 to 6.0 days and t1/2was within 4.11 to 5.01 days across cohorts. Cmax,AUC0-t,and AUC0-∞increased approximately in a dose-proportional manner, see Table 1 and Figure 2. Serum free PCSK9 was almost completely inhibited after ebronucimab injection. The lowest level of free PCSK9 was observed around 2 days post administration and maintained at a low level 14-22 days post injection, see Figure 3.ImmunogenicityA total of 3 subjects were tested ADA positive at least once during the study (75 mg, 1 subject; 500 mg, 2 subjects). The incidence of ADAs in subjects treated with ebronucimab was 12.5 % (3/24).Conclusions:Ebronucimab was well tolerated in healthy subjects and no special safety signal was identified during the study.

A Pharmacokinetic Study of Intramuscular Administration of Bulleyaconitine A in Healthy Volunteers

Dose-dependent Pharmacokinetics of Bulleyaconitine A in Rats.

Determination of Bulleyaconitine A in Plasma by a Sensitive LC–MS/MS Method and Its Application to an Oral Pharmacokinetic Study in Rats

Determination of bulleyaconitine A in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry.

Sensitive Quantification of Bulleyaconitine A in Human Serum by Liquid Chromatography-Tandem Mass Spectrometry.

Pharmacokinetics of Single Dose Intramuscularly Injected Ziprasidone Mesylate in Healthy Volunteers

Bulleyaconitine A is a sensitive substrate and competitive inhibitor of CYP3A4: One of the possible explanations for clinical adverse reactions

Efficacy and safety of bulleyaconitine A on patients with osteoarthritis

Long-acting bulleyaconitine A microspheres via intra-articular delivery for multidimensional therapy of rheumatoid arthritis

Effect of Bulleyaconitine A(BLA) on Adjuvant Arthritis Rats

Inhibitory Effect of Bulleyaconitine A on Some Immune Function in Balb/c Mice

A Randomized Pharmacokinetic Study in Healthy Male Subjects Comparing a High-concentration, Citrate-free SB5 Formulation (40 mg/0.4 ml) and Prior SB5 (Adalimumab Biosimilar)

Skin permeability and anti-inflammatory analgesic activities of bulleyaconitine A liposomes

Synthesis and Evaluation of a Series of New Bulleyaconitine A Derivatives as Analgesics

Abstract 9318: The Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Ebronucimab in Healthy Volunteers: Result From a Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Dose-Escalation Study

Bulleyaconitine A depresses neuropathic pain and potentiation at C-fiber synapses in spinal dorsal horn induced by paclitaxel in rats

Effect of Bulleyaconitin A on the Chemotaxis of Mouse Peritoneal Macrophages

Effects of Bulleyaconitine A on Gastrointestinal Mucosa in Rats

Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)

Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B-Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein, in Healthy Chinese Subjects

Pharmacokinetics, Pharmacodynamics, Tolerability and Safety of Single Doses of Bivalirudin in Healthy Chinese Subjects.